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Abstract
Microalbuminuria (MA) is a predictor of excess cardiovascular morbidity and mortality in
non-diabetic hypertensive patients. This study evaluated the electrocardiographic correlates of
MA in adult non-diabetic Nigerians with essential hypertension. Ninety-six newly diagnosed
hypertensive patients who consented and met the inclusion criteria for the study were recruited.
Ninety-six age- and gender-matched normotensive controls were also studied. Resting 12-lead
electrocardiogram of all patients and controls was done and the tracings analyzed by the
authors for left ventricular hypertrophy with or without repolarization abnormalities, QTc
prolongation, conduction abnormalities and cardiac arrhythmias such as atrial fibrillation.
MA was present in 31 (32.3%) of the hypertensive patients and in only six (6.25%) of the
normotensive controls. Electrocardiographic left ventricular hypertrophy (ECG LVH) was sig-
nificantly more commonly found in patients with MA than in patients without it (74.2% vs
40%, p = 0.002). Left ventricular hypertrophy with ischemic pattern was significantly more
frequent in the microalbuminuric hypertensive subset than in non-microalbuminuric patients
(32.3% vs 13.8%, p = 0.03). The mean QTc were 0.464 ± 0.02 s and 0.428 ± 0.017 s for
microalbuminuric and non-microalbuminuric patients respectively (p = 0.01). This study
shows that MA is associated with ECG abnormalities such as left ventricular hypertrophy,
ischemic pattern ST-T changes and QTc prolongation. This subset of hypertensive patients
constitutes a higher risk group and needs intensive monitoring and follow-up. Screening for
MA should constitute part of the routine investigation of adult Nigerians with hypertension.
(Cardiol J 2010; 17, 3: 281–287)
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Introduction
Hypertension is recognized as a common cardio-
vascular disease and a major risk factor for congestive
heart failure, ischemic heart disease, chronic renal
failure and stroke. Hypertension is defined as per-
sistent elevation in blood pressure ≥ 140/90 mm Hg
[1]. The prevalence in Nigeria, which was 15.3%
(urban) and 10.6% (rural) in the general population
[2, 3] was later estimated in the hospital setting to
be 17–20% [4]. Cardiac damage is a common early
complication of hypertension [5]. Electrocardiogram
(ECG) is a useful tool to detect cardiac changes as-
sociated with hypertension [6, 7]. Microalbuminuria
(MA) was first noticed in poorly controlled hyper-
tensive individuals in 1974 [8]. MA is defined as
urinary albumin excretion (UAE) of 20–200 µg/min
(30–300 mg/day) or albumin creatinine ratio of
3–30 mg/mmoL (30–300 mg/g) [9]. MA is an indi-
cator of generalized vascular damage and a marker
of cardiovascular complications in hypertension
[10]. This phenomenon has been associated with
a higher incidence of morbid and mortal cardiovas-
cular events [11]. The Prevention of REnal and
Vascular END-stage Disease (PREVEND) study
showed that MA was independently associated with
ischemic ECG abnormalities [12].
MA and ECG abnormalities represent two dif-
ferent forms of target organ damage due to hyper-
tension. The objective of the study was to investi-
gate and evaluate the ECG abnormalities associat-
ed with MA in non-diabetic hypertensive adult
Nigerians.
Methods
A prospective study of 96 newly diagnosed non-
diabetic hypertensive patients were consecutively
enrolled and compared with age- and sex-matched
healthy normotensive individuals. The study was
carried out between January 2003 and June 2004 at
the Cardiology Unit of the University of Ilorin
Teaching Hospital, Ilorin, Nigeria. Both oral and
written consent was obtained from all participants
and research approval was also obtained from the
institutional research and ethics committee. Some
exclusion criteria for the study were: previous use
of antihypertensive medications, diabetes mellitus
(fasting plasma glucose ≥ 7.0 mmol/L or use of in-
sulin and/or hypoglycaemic medications) [13], re-
nal or endocrine disease, overt proteinuria (as dem-
onstrated by conventional dipsticks), abnormal uri-
nary sediments on microscopy, congestive heart
failure, myocardial infarction, abnormal liver func-
tion tests, obesity and use of medications that can
cause ECG changes, e.g. antiarrythmic drugs, tri-
cyclic antidepressants and macrolide antibiotics.
Clinical evaluation, definition
and measurements
All participants underwent a detailed history
and a thorough physical examination, including an-
thropometry. Laboratory assessment of cardiovas-
cular risk factors and other relevant investigations
were carried out. Body mass index (BMI) was cal-
culated as weight (in kilograms) divided by the
square of height (in meters). Obesity was defined
as a BMI ≥ 30 kg/m2 [14]. Waist-to-hip ratio was
calculated as the ratio of the minimum waist circum-
ference (a point between the upper third and the low-
er two thirds of the distance from umbilicus to xi-
phisternum) and the maximal hip circumference (the
most prominent point of the gluteal region) [15].
Blood pressures were measured using a mer-
cury column sphygmomanometer and a cuff of ap-
propriate size. A standardized protocol was fol-
lowed, in which systolic (SBP) and diastolic (DBP)
blood pressures were measured on the left arm af-
ter participants had been seated for at least five
minutes. Three measurements were done at least five
minutes apart and the mean value used for the study.
Hypertension was defined as SBP ≥ 140 mm Hg
and/or DBP ≥ 90 mm Hg, or use of antihyperten-
sive medications [1, 16, 17]. Blood samples were
collected for fasting plasma glucose using the colo-
rimetric method. Blood samples were also analyzed
for serum total cholesterol (TC), triglyceride (TG),
low density cholesterol (LDL) and high density cho-
lesterol (HDL) using Rapid Analyzer 50 machine.
Serum urea and creatinine and creatinine clearance
were also done for all participants.
Electrocardiogram
Resting 12-lead ECG of all patients and con-
trols were recorded using 3-channel Schiller Car-
diovit-10 machine at a sensitivity of 10 mm/mV and
a paper speed of 25 mm/s. Rhythm strip using stan-
dard lead II was equally done at a paper speed of
50 mm/s for QT measurement. Corrected QTc
(QTc) was then derived using the Bazett’s [18]
formula below, where QTo is the observed QT:
QTc = QTo [s]/÷R-R [s].
The ECG tracings were read using a manual
caliper. ECG left ventricular hypertrophy (LVH) was
diagnosed using Sokolow and Lyon’s criteria [19, 20].
Left atrial enlargement (LAE) was based on findings
of ‘P-mitrale’, positive ‘Morris index’ [21], ‘Macruz
index’ > 3.0 [20, 22] or any combinations of these.
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Microalbuminuria testing
MA was determined using the Micra Test II
test strips (Boehringer Manneheim GMBh, Man-
nheim, Germany). This dipstick has been found to
be the fastest, most accurate and, relatively, cheap-
est way to screen patients for the presence of MA [23].
There are four color blocks on the test strip corre-
sponding to negative (or 0), 20, 50 and 100 mg/L of
albumin. The test was done on three consecutive
first morning voided urine samples collected at
three weekly intervals. MA was considered to be
present when two of the three urine samples test-
ed produced a reaction color corresponding to
20 mg/L or more. The mean value of the MA was
also recorded for each participant.
Data analysis
The data collected was analyzed with SPSS 10.5
software. Percentages and proportions were used
to describe categorical variables while means and
standard deviations were used for numerical
variables. Student’s t test and c2 were used to an-
alyze differences between variables as appropri-
ate. P < 0.05 was taken as indicating statistical
significance.
Results
The prevalence of MA in the hypertensive
group was 32.3% and 6.25% in the controls. The
mean age (±SD) of the patients was 49.7 ± 12.7
years with a range of 24–77 years and the male to
female ratio was 1.34:1.0. The mean age (±SD) of
the controls was 46.1 ± 13 years with a range of
20–74 years. There was no statistically significant
difference between the mean ages (±SD) of pa-
tients and controls (p = 0.06). There was also no
statistically significant difference between the mean
ages (±SD) of patients with MA and those without
MA (52.5 ± 11.9 vs 48.3 ± 13.0, p = 0.1). Table 1
enumerates other characteristics of the patients and
the controls. Patients with MA had statistically sig-
nificant higher DBP (p = 0.03) than those without
MA. However, the difference between SBP (p =
= 0.07) and pulse pressure (PP) (p = 0.06) was not
statistically significant (Table 2). MA patients also
had significantly lower HDL and higher TC and LDL
than their counterparts without MA. But the means
of TG were not statistically different between MA
and non-MA groups. Patients with MA were more
likely to have ECG LVH than patients without it
(74.2% vs 40%). LVH with ischemic pattern was sig-
nificantly more common in MA hypertensive pa-
tients than those without MA (32.3% vs 13.8%,
p = 0.03; Table 3). Although 13 (41.9%) MA pa-
tients had LAE, there was no significant difference
when compared to non-MA patients (p = 0.06). But
when compared to the controls, LAE was signifi-
cantly more common (p = 0.0001; Table 4). Five
(16.1%) patients with MA and the same number
without MA (7.7%) had QTc prolongation (p = 0.01).
The means QTc were 0.464 ± 0.02 s and 0.428 ±
± 0.017 s for MA and non-MA patients respectively
(Table 4). Arrhythmias such as atrial fibrillation,
Table 1. Characteristics of patients and controls.
Patients Controls P
Male Female Total Male Female Total
(n = 52)  (n = 44)  (n = 96)  (n = 49)  (n = 47)  (n = 96)
Mean age 51.2±10.1 48.2±8.8 49.7±12.7 49.6±12.3 42.6±10.4 46.1±13.0 0.2
(year)
Mean SBP 164.5±14.2* 155.5±15.1* 160.0±15.0 132.4±9.7* 125.6±8.2* 129.0±10.0 0.01
[mm Hg]
Mean DBP 111.5±10.1* 103.3±11.8 107.4±10.5 82.1±5.9* 78.3±7.1 80.2±6.9 0.01
[mm Hg]
Mean PP 53.0±10.7 52.2±12.9 52.6±8.6 50.3±6.5 47.3±7.6 48.8±7.1 0.1
[mm Hg]
TC [mmol/L] 4.55±0.76* 4.37±0.81* 4.46±0.79 3.50±0.41* 3.28±0.38* 3.39±0.42 0.02
TG [mmol/L] 1.28±0.27 1.24±0.29 1.26±0.32 1.23±0.12 1.17±0.11 1.20±0.18 0.4
LDL [mmol/L] 3.29±0.68* 3.11±0.79* 3.20±0.77 2.52±0.42* 2.36±0.39* 2.44±0.38 0.03
HDL [mmol/L] 1.10±0.22* 1.02±0.26* 1.06±0.25 1.27±0.17* 1.21±0.19* 1.24±0.13 0.05
CL [mL/min] 81.5±19.4 73.3±16.7 77.42±20.72 88.7±14.2 79.9±13.8 84.28±17.10 0.06
CR [µmol/L] 95.9±12.1 90.9±13.2 93.4±11.5 88.7±10.6 85.3±11.2 87.0±10.8 0.5
*p < 0.05; SBP — systolic blood pressure; DBP — diastolic blood pressure; PP — pulse pressure; TC — total cholesterol; TG — trigliceride; LDL — low
density protein; HDL — high density protein; CL — creatine clearance; CR — creatinine
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Table 2. Characteristics of patients with and without microalbuminuria (MA).
Patients with MA Patients without MA P
Male Female Total Male Female Total
(n = 18)  (n = 13)  (n = 31)  (n = 37)  (n = 18)  (n = 65)
Mean age 54.9±8.8 50.6±9.2 52.5±11.9 49.5±10.1 47.8±8.7 48.3±13.0 0.1
(year)
Mean SBP 185.2±18.4 179.5±20.1 182.2±20.4 162.8±17.9 168.1±18.3 168.3±22.1 0.07
[mm Hg]
Mean DBP 120.3±20.5* 119.7±17.0* 120.5±18.7 100.8±15.1* 100.4±12.1* 102±14.9 0.03
[mm Hg]
Mean PP 64.7±10.9 80.1±12.4 81.8±11.7 60.3±13.1 66.5±105 66.4±10.2 0.06
[mm Hg]
TC [mmol/L] 5.05±0.87* 4.94±0.78* 5.0±0.56 4.11±0.62* 3.99±0.53* 4.05±0.5 0.04
TG [mmol/L] 1.47±0.21 1.35±0.24 1.41±0.35 1.39±0.25 1.25±0.29 1.32±0.29 0.2
LDL [mmol/L] 4.08±0.51* 3.90±0.49* 3.99±0.49 2.52±0.42* 2.36±0.39* 2.44±0.38 0.001
HDL [mmol/L] 0.93±0.18* 0.89±0.17* 0.91±0.16 1.27±0.17* 1.21±0.19* 1.24±0.13 0.01
CL [mL/min] 68.7±12.5* 62.3±10.8* 63.6±11.5 79.7±13.1* 71.5±11.4* 72.5±12.6 0.02
CR [µmol/L] 96.4±14.1 95.9±13.7 94.3±10.6 94.1±13.2 93.1±12.9 93.5±11.7 0.5
*p < 0.05; SBP — systolic blood pressure; DBP — diastolic blood pressure; PP — pulse pressure; TC — total cholesterol; TG — trigliceride; LDL — low
density protein; HDL — high density protein; CL — creatine clearance; CR — creatinine
Table 3. ECG chamber hypertrophy and QTc in patients with and without microalbuminuria (MA).
Patients with MA Patients without MA P
Male Female Total Male Female Total
(n = 18)  (n = 13)  (n = 31)  (n = 37)  (n = 18)  (n = 65)
LVH with 7 (38.9%)* 3 (23.1%) 10 (32.3%) 5 (13.5%)* 4 (22.2%) 9 (13.8%) 0.03
ischemic pattern
LVH without 7 (38.9%)* 6 (46.2%) 13 (41.9%) 8 (21.6%)* 9 (50.0%) 17 (26.2%) 0.01
ischemic pattern
LAE 11 (61.1%)* 2 (15.4%)* 13 (41.9%) 9 (24.3%)* 6 (33.3%)* 15 (23.1%) 0.06
BAE 2 (11.1%)* — 2 (6.5%) 1 (2.7%)* — 1 (1.5%)
Mean QTc 0.471±0.014* 0.460±0.019 0.464±0.02 0.435±0.01* 0.0426±0.13 0.428±0.017 0.001
Number with 4 (22.2%)* 1 (7.7%) 5 (16.1%) 3 (8.1%)* 2 (11.1%) 5 (7.7%) 0.01
QTc prolongation
*p < 0.05; LVM — left ventricular hypertrophy; LAE — left atrial enlargement; BAE — biatrial enlargement
Table 4. ECG chamber hypertrophy and QTc in patients with microalbuminuria (MA) and controls.
Patients with MA Controls P
Male Female Total Male Female Total
(n = 18)  (n = 13)  (n = 31)  (n = 49)  (n = 47)  (n = 96)
LVH with 7 (38.9%) 3 (23.1%) 10 (32.3%) — — —
ischemic pattern
LVH without 7 (38.9%)* 6 (46.2%)* 13 (41.9%) 5 (10.2%)* 5 (10.6%)* 10 (10.4%) 0.07
ischemic pattern
LAE 11 (61.1%)* 2 (15.4%)* 13 (41.9%) 2 (4.1%)* 1 (2.1%)* 3 (3.1%) 0.0001
BAE 2 (11.1%) — 2 (6.5%) — — —
Mean QTc 0.471±0.014* 0.460±0.019* 0.464±0.02 0.392±0.18* 0.410±0.02* 0.395±0.012 0.001
Number with 4 (22.2%)* 1 (7.7%) 5 (16.1%) 1 (2.0%)* 1 (2.1%) 2 (2.1%) 0.006
QTc prolongation
*p < 0.05; LVM — left ventricular hypertrophy; LAE — left atrial enlargement; BAE — biatrial enlargement
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premature ventricular complex (PVC) and prema-
ture atrial complex (PAC) were more frequent in pa-
tients with MA than in those without MA (Table 5).
PVC was significantly more frequent in MA than
non-MA patients (p = 0.04). Intraventricular con-
duction abnormalities were more common in pa-
tients with MA than their counterparts without MA
and the controls (Table 5). Left bundle branch block
was present in four (12.9%) and three (4.6%) MA
and non-MA patients respectively (p = 0.05). Al-
though PAC (9.7% vs 2.1%, p = 0.2), and most of
the heart blocks i.e. 1st degree atrioventricular block
(6.4% vs 4.2%, p = 0.4), left anterior hemiblock
(12.9% vs 5.2%, p = 0.06), right bundle branch block
(6.4% vs 4.2%, p = 0.4), were more frequent in pa-
tients with MA than in the controls, the differenc-
es were not significant.
There was a significant positive correlation
between MA and DBP (r = 0.38, p = 0.018), QTc
(r = 0.67, p = 0.01), LVH (r = 0.42, p = 0.021), TC
(r = 0.51, p = 0.019) and LDL (r = 0.49, p = 0.020).
A significant negative correlation existed between
MA and HDL (r = –0.27, p = 0.037) and creatinine
clearance (r = –0.24, p = 0.040); while no signifi-
cant relationship was found with regard to age, SBP
(r = 0.22, p = 0.055), PP (r = 0.14, p = 0.089),
TG (r = 0.11, p = 0.094) and creatinine (r = 0.73,
p = 0.296).
Discussion
This study has shown that MA is associated
with ECG abnormalities and other risk factors for
cardiovascular morbidity and mortality in non-dia-
betic adult Nigerians with hypertension. This ac-
cords with previous research [10–12, 24–26]. The
prevalence of MA (32.3%) is not too far from the
25.4% found in a South African study [27]. Howev-
er, it is important to acknowledge that the settings
of the two studies were different. Patients with MA
had significantly higher DBP than those without
MA, and DBP was positively and significantly cor-
related with MA. This finding is at variance with the
study by Akinsola et al. [24] which reported a sig-
nificant positive correlation between MA and SBP
and not DBP. Although SBP has remained a more
consistent determinant of MA in hypertensives,
some other studies have also implicated DBP and
PP. A study of 539 Chinese women and 795 men
showed that DBP was independently correlated
with UAE [28, 29].
In this study, hypertensive patients with MA
were more likely to have ECG LVH than both the
patients without MA and the normotensive controls.
In fact, ECG LVH with ischemic pattern was sig-
nificantly more common in the subset with MA.
There was also a significant positive correlation
between MA and LVH. This finding was similar to
the report of PREVEND study which showed that
MA was independently associated with ischemic
electrocardiographic abnormalities in a large non-
diabetic population [12]. Also, Salles et al. [30] found
that the presence of ECG strain was associated with
higher 24-hour MA. ECG LVH has been shown to
be an independent risk factor for sudden cardiac
death [24]. This may partly explain the excess car-
Table 5. Arrhythmias and heart blocks in patients with and without microalbuminuria (MA).
Patients with MA Patients without MA P
Male Female Total Male Female Total
(n = 18)  (n = 13)  (n = 31)  (n = 37)  (n = 18)  (n = 65)
AF 1 (5.6%) — 1 (3.2%) — 1 (5.6%) 1 (1.5%)
PAC 2 (11.1%) 1 (7.7%) 3 (9.7%) 3 (8.1%) 2 (11.1%) 5 (7.7%) 0.6
PVC 6 (33.3%)* 2 (15.4%) 8 (25.8%) 3 (8.1%)* 1 (5.6%) 5 (7.7%) 0.03
1st degree AVB 1 (5.6%) 1 (7.7%) 2 (6.4%) 1 (2.7%) 3 (16.7%) 4 (6.2%) 0.4
2nd degree AVB 1 (5.6%) — 1 (3.2%) — — —
3rd degree AVB — — — — — —
LAHB alone 2 (11.1%) 2 (15.4%) 4 (12.9%) 5 (13.5%) 3 (16.7%) 8 (12.3%) 0.4
LPHB alone 1 (5.6%) — 1 (3.2%) — — —
RBBB 1 (5.6%) 1 (7.7%) 2 (6.4%) 2 (5.4%) 3 (16.7%) 5 (7.7%) 0.2
LBBB 3 (16.7%) 1 (7.7%) 4 (12.9%) 3 (8.1%) — 3 (4.6%) 0.05
LAHB + RBBB 1 (5.6%) — 1 (3.2%) 1 (2.7%) — 1 (1.5%)
LPHB + RBBB — — — — — —
TFB — — — — — —
*p < 0.05; AF — atrial fibrillation; PAC — premature atrial complex; PVC — premature ventricular complex; AVB — atrioventricular block; LAHB — left
anterior hemiblock; LPHB — left posterior hemiblock; RBBB — right bundle branch block; LBBB — left bundle branch block; TFB — trifasciular block
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diovascular morbidity and mortality associated with
MA in non-diabetic hypertensive patients. In fact,
Dell’omo et al. [31] concluded in their study that
LVH explained, at least in part, the predictive power
of MA for morbid events. The conferment of great-
er cardiovascular risk when LVH is associated with
ST-T wave changes has been documented in many
studies [32, 33]. Opadijo et al. [33] concluded that
LVH with ST-T wave changes signified a higher
coronary risk in adult Nigerians.
It is also evident from this study that patients
with MA had significantly longer mean QTc than
their counterparts without MA. QTc prolongation
was more frequent in the former than in the latter
group. QTc also showed significant positive corre-
lation with MA. The significance of this finding is
that hypertensive patients with MA are more like-
ly to develop arrhythmias that are associated with
QTc prolongation such as PVC and ventricular ta-
chycardia. It also suggests that MA has additional
value to conventional risk indicators in predicting
cardiovascular events in non-diabetic hypertensive
patients. Patients with MA are also more likely to
have PVC than patients without MA. Major ECG
abnormalities in hypertension may be as a result of
pressure overload and atherosclerotic vascular dam-
age and are considered predictors of future vascular
events [34]. Pontremoli et al. [35] also revealed that
MA has a significant and independent role in target
organ damage, particularly ECG abnormalities.
Our study also revealed that patients with MA
had significantly higher TC and LDL, and lower
HDL, than patients without MA and the controls.
MA was positively and significantly correlated with
TC and LDL and negatively and significantly cor-
related with HDL. This finding is consistent with
the reports of previous studies. Biggazi et al. [36]
reported that dyslipidemia was associated with
MA and added to the cardiovascular risk in hyper-
tension.
Conclusions
MA signifies ECG abnormalities such as ECG
LVH, QTc prolongation and ventricular arrhythmias
in adult non-diabetic Nigerians with hypertension.
It indicates excess cardiovascular morbidity and
mortality. Hence the subset of adult Nigerian hy-
pertensive patients with MA constitutes a higher
risk group and needs close monitoring and follow-
up. These patients may also benefit from antihyper-
tensive drugs that have been proven to be effective
in reducing albuminuria. We recommend routine
screening for MA in newly diagnosed hypertensive
patients and at regular intervals during follow-up.
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